Anna Berkenblit - 30 Jun 2023 Form 4 Insider Report for ImmunoGen, Inc.

Reporting relationship: SVP & CHIEF MEDICAL OFFICER
Issuer ticker: N/A
Reported as of: 30 Jun 2023
Net transaction value: +$13,219
SEC form: 4
Accepted by SEC: 05 Jul 2023, 17:56:29 UTC
Prior SEC filing: 22 May 2023
Next SEC filing: 06 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Renee Lentini, Attorney-in-Fact

Key filing fact

Anna Berkenblit filed Form 4 for ImmunoGen, Inc. on 05 Jul 2023.

Key facts

This page summarizes Anna Berkenblit's Form 4 filing for ImmunoGen, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Jul 2023, 17:56.

Change

Previous filing in this sequence was filed on 22 May 2023.
Current net transaction value: +$13,219.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMGN transaction

Common Stock

Award

Transaction value: $13,219
Shares: +3,264
Change %: +2.9%
Price: $4.05^*
Shares after: 113,935
Date: 30 Jun 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from January 1, 2023 through June 30, 2023.

Footnote F2

In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 3, 2023.